首页 > 最新文献

Singapore family physicians最新文献

英文 中文
A New Lease of Life - Living With Disability and Renal Dialysis 新生命-与残疾和肾透析共存
Pub Date : 2019-09-21 DOI: 10.33591/SFP.45.6.UP1
Rose Fok Wai Yee, Lowon Luke, F. Vasanwala
Mr Q is a 59-year old single male, pre-morbid independent in activities of daily living, community ambulant with a history of uncontrolled diabetes mellitus (DM) along with complications of osteomyelitis and chronic kidney disease (CKD). I was part of the family medicine team providing inpatient medical care for Mr Q, where he was transferred for rehabilitation following his below knee amputation (BKA). SITUATION AND BACKGROUND
Q先生是一名59岁单身男性,发病前能独立进行日常生活活动,常去社区走动,有糖尿病(DM)未控制病史,并伴有骨髓炎和慢性肾脏疾病(CKD)并发症。我是家庭医疗小组的一员,为Q先生提供住院医疗护理,在那里他被转移到膝下截肢后进行康复治疗。情况与背景
{"title":"A New Lease of Life - Living With Disability and Renal Dialysis","authors":"Rose Fok Wai Yee, Lowon Luke, F. Vasanwala","doi":"10.33591/SFP.45.6.UP1","DOIUrl":"https://doi.org/10.33591/SFP.45.6.UP1","url":null,"abstract":"Mr Q is a 59-year old single male, pre-morbid independent in activities of daily living, community ambulant with a history of uncontrolled diabetes mellitus (DM) along with complications of osteomyelitis and chronic kidney disease (CKD). I was part of the family medicine team providing inpatient medical care for Mr Q, where he was transferred for rehabilitation following his below knee amputation (BKA). SITUATION AND BACKGROUND","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"151 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131921088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Role of Airway Inflammation in Asthma 气道炎症在哮喘中的作用
Pub Date : 2019-09-21 DOI: 10.33591/SFP.45.6.U2
Liman Fang
Uncontrolled airway inflammation contributes to persistent asthma symptoms and risks of exacerbations and airway remodelling. many asthma patients are non-adherent to inhaled corticosteroid (ICS) treatment and have a discordance between subjective symptom perception versus actual control of asthma, i.e. airway inflammation. Objective measurements of airway inflammation, e.g. fENO and sputum cell count quantification can aid clinical management. Nonetheless, there are many limitations in the tests’ availability and interpretation. Hence, these tests are used mainly for difficultto-treat or severe airway diseases. In the 2019 Global Initiative for Asthma (GINA) strategy report, short-acting beta-agonist (SABA) monotherapy is no longer recommended in Step 1 and ICS is recommended across all asthma severity to emphasize the importance of controlling airway inflammation. Doctors should discuss and recommend the most appropriate ICS therapy (dosing regimen and inhaler device) that is acceptable to the patient, to promote adherence. Appropriate use of ICS is crucial in achieving the management targets of asthma: maintenance symptom control and prevention of asthma risks.
不受控制的气道炎症会导致持续的哮喘症状和加重和气道重塑的风险。许多哮喘患者对吸入皮质类固醇(ICS)治疗没有依从性,并且主观症状感知与哮喘的实际控制(即气道炎症)之间存在不一致。气道炎症的客观测量,如fENO和痰细胞计数定量可以帮助临床管理。然而,在测试的可用性和解释方面存在许多限制。因此,这些测试主要用于难以治疗或严重的气道疾病。在2019年全球哮喘倡议(GINA)战略报告中,短效β受体激动剂(SABA)单药疗法在第1步中不再推荐,并建议在所有哮喘严重程度中使用ICS,以强调控制气道炎症的重要性。医生应讨论并推荐患者可接受的最合适的ICS治疗(给药方案和吸入器装置),以促进依从性。适当使用ICS对于实现哮喘的管理目标:维持症状控制和预防哮喘风险至关重要。
{"title":"The Role of Airway Inflammation in Asthma","authors":"Liman Fang","doi":"10.33591/SFP.45.6.U2","DOIUrl":"https://doi.org/10.33591/SFP.45.6.U2","url":null,"abstract":"Uncontrolled airway inflammation contributes to persistent asthma symptoms and risks of exacerbations and airway remodelling. many asthma patients are non-adherent to inhaled corticosteroid (ICS) treatment and have a discordance between subjective symptom perception versus actual control of asthma, i.e. airway inflammation. Objective measurements of airway inflammation, e.g. fENO and sputum cell count quantification can aid clinical management. Nonetheless, there are many limitations in the tests’ availability and interpretation. Hence, these tests are used mainly for difficultto-treat or severe airway diseases. In the 2019 Global Initiative for Asthma (GINA) strategy report, short-acting beta-agonist (SABA) monotherapy is no longer recommended in Step 1 and ICS is recommended across all asthma severity to emphasize the importance of controlling airway inflammation. Doctors should discuss and recommend the most appropriate ICS therapy (dosing regimen and inhaler device) that is acceptable to the patient, to promote adherence. Appropriate use of ICS is crucial in achieving the management targets of asthma: maintenance symptom control and prevention of asthma risks.","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114636637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spirometry in Asthma 哮喘的肺活量测定
Pub Date : 2019-09-21 DOI: 10.33591/SFP.45.6.U3
Quek Li Ling, Pang Pee Hwee
{"title":"Spirometry in Asthma","authors":"Quek Li Ling, Pang Pee Hwee","doi":"10.33591/SFP.45.6.U3","DOIUrl":"https://doi.org/10.33591/SFP.45.6.U3","url":null,"abstract":"","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126172841","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Asthma and Inflammation 哮喘和炎症
Pub Date : 2019-09-01 DOI: 10.33591/SFP.45.6.U1
A. Chan
Asthma is a chronic inflammatory airway disease, for which the cornerstone of asthma therapy is inhaled corticosteroids. however, long term clinical outcomes are variable, and not all patients respond optimally to corticosteroids. Underpinning this observation is that asthma is a heterogeneous disease consisting of phenotypes that are driven by different inflammatory pathways. In this article, we will discuss the different inflammatory mechanisms of asthma to better define patient characteristics and help improve patient outcomes with newer specific-targeted asthma therapies.
哮喘是一种慢性炎症性气道疾病,哮喘治疗的基石是吸入皮质类固醇。然而,长期的临床结果是可变的,并不是所有的患者对皮质类固醇反应最佳。支持这一观察结果的是,哮喘是一种异质性疾病,由不同炎症途径驱动的表型组成。在本文中,我们将讨论哮喘的不同炎症机制,以更好地定义患者特征,并帮助通过新的特异性靶向哮喘治疗改善患者的预后。
{"title":"Asthma and Inflammation","authors":"A. Chan","doi":"10.33591/SFP.45.6.U1","DOIUrl":"https://doi.org/10.33591/SFP.45.6.U1","url":null,"abstract":"Asthma is a chronic inflammatory airway disease, for which the cornerstone of asthma therapy is inhaled corticosteroids. however, long term clinical outcomes are variable, and not all patients respond optimally to corticosteroids. Underpinning this observation is that asthma is a heterogeneous disease consisting of phenotypes that are driven by different inflammatory pathways. In this article, we will discuss the different inflammatory mechanisms of asthma to better define patient characteristics and help improve patient outcomes with newer specific-targeted asthma therapies.","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"119 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124610563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ten readings on ASThmA AND INfLAmmATION – NEw UpDATES 关于哮喘和炎症的十个读数-新的更新
Pub Date : 2019-09-01 DOI: 10.33591/sfp.45.6.ur
L. Goh
{"title":"Ten readings on ASThmA AND INfLAmmATION – NEw UpDATES","authors":"L. Goh","doi":"10.33591/sfp.45.6.ur","DOIUrl":"https://doi.org/10.33591/sfp.45.6.ur","url":null,"abstract":"","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"146 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131763556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adolescent Eating Disorder in Primary Care - A Case Study 青少年饮食失调在初级保健-个案研究
Pub Date : 2019-09-01 DOI: 10.33591/sfp.45.6.up2
A. Han, R. Ramachandran, L. Goh
{"title":"Adolescent Eating Disorder in Primary Care - A Case Study","authors":"A. Han, R. Ramachandran, L. Goh","doi":"10.33591/sfp.45.6.up2","DOIUrl":"https://doi.org/10.33591/sfp.45.6.up2","url":null,"abstract":"","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127286138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seronegative Spondyloarthropathies 血清反应阴性的Spondyloarthropathies
Pub Date : 2019-04-01 DOI: 10.33591/sfp.43.2.u3
L. W. Koh
{"title":"Seronegative Spondyloarthropathies","authors":"L. W. Koh","doi":"10.33591/sfp.43.2.u3","DOIUrl":"https://doi.org/10.33591/sfp.43.2.u3","url":null,"abstract":"","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"76 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122601991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular Risk Calculators: Back to Basics 心血管风险计算器:回归基础
Pub Date : 2019-01-01 DOI: 10.33591/sfp.43.1.u2
P. Ting
Cardiovascular disease (CVD) is a leading global cause of mortality and morbidity. Risk assessment of asymptomatic individuals plays an important role in the primary prevention of CVD and its complications by guiding management decisions, in particular the decision to use statins or antiplatelet agents, as well as more controversially, the target level for risk factors such as hypertension and cholesterol. Timely and regular risk assessments also identify the development of physiological disturbances such as pre-hypertension, pre-diabetes, dyslipidaemias, clinical obesity and metabolic syndrome, which can be asymptomatic in the early stages, but may lead to increased risk for many ageing-related degenerative diseases, including CVD. These physiological mal-adaptations are remarkably responsive to behavioural lifestyle interventions at an early stage, and may be stabilised or even reversed without medications. This article describes the why and how of assessing CVD risk and a suggested framework for management, including the appropriate use of behavioural lifestyle interventions as first-line treatment. It also describes the various risk scores available, their differences and limitations and how to best use them in clinical practice. More research is required regarding the use of non-traditional and emerging markers of CVD risk such as carotid intima-media thickness, coronary artery calcium scoring, hsCRP, ankle brachial index, Apo-B, albuminuria, and how they may be incorporated into existing risk models.
心血管疾病(CVD)是全球主要的死亡和发病原因。无症状个体的风险评估在CVD及其并发症的一级预防中起着重要作用,通过指导管理决策,特别是决定使用他汀类药物或抗血小板药物,以及更有争议的高血压和胆固醇等危险因素的目标水平。及时和定期的风险评估还可以确定生理障碍的发展,如高血压前期、糖尿病前期、血脂异常、临床肥胖和代谢综合征,这些疾病在早期可能没有症状,但可能导致许多与衰老相关的退行性疾病(包括心血管疾病)的风险增加。这些生理上的不良适应在早期阶段对行为生活方式干预有明显的反应,并且可以在没有药物的情况下稳定甚至逆转。本文描述了评估心血管疾病风险的原因和方法,以及建议的管理框架,包括适当使用行为生活方式干预作为一线治疗。它还描述了各种可用的风险评分,它们的差异和局限性,以及如何在临床实践中最好地使用它们。关于非传统和新兴的心血管疾病风险标志物的使用,如颈动脉内膜-中膜厚度、冠状动脉钙评分、hsCRP、踝肱指数、载脂蛋白b、蛋白尿,以及如何将它们纳入现有的风险模型,还需要进行更多的研究。
{"title":"Cardiovascular Risk Calculators: Back to Basics","authors":"P. Ting","doi":"10.33591/sfp.43.1.u2","DOIUrl":"https://doi.org/10.33591/sfp.43.1.u2","url":null,"abstract":"Cardiovascular disease (CVD) is a leading global cause of mortality and morbidity. Risk assessment of asymptomatic individuals plays an important role in the primary prevention of CVD and its complications by guiding management decisions, in particular the decision to use statins or antiplatelet agents, as well as more controversially, the target level for risk factors such as hypertension and cholesterol. Timely and regular risk assessments also identify the development of physiological disturbances such as pre-hypertension, pre-diabetes, dyslipidaemias, clinical obesity and metabolic syndrome, which can be asymptomatic in the early stages, but may lead to increased risk for many ageing-related degenerative diseases, including CVD. These physiological mal-adaptations are remarkably responsive to behavioural lifestyle interventions at an early stage, and may be stabilised or even reversed without medications. This article describes the why and how of assessing CVD risk and a suggested framework for management, including the appropriate use of behavioural lifestyle interventions as first-line treatment. It also describes the various risk scores available, their differences and limitations and how to best use them in clinical practice. More research is required regarding the use of non-traditional and emerging markers of CVD risk such as carotid intima-media thickness, coronary artery calcium scoring, hsCRP, ankle brachial index, Apo-B, albuminuria, and how they may be incorporated into existing risk models.","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"49 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126846642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updates in Hypertension Management - 2017 高血压管理最新进展- 2017
Pub Date : 2019-01-01 DOI: 10.33591/sfp.43.1.u3
T. Lau
Management of hypertension will continue to evolve as new studies provide us more evidence on many relevant aspects of care for this very common condition. To define hypertension, we need to be able to measure blood pressure (BP) accurately and make it easily reproducible. The mercury sphygmomanometer has been a standard tool to measure BP, but it is evident that it will be phased out soon and replaced by electronic BP devices — both for clinic and home use. There is increasingly more awareness of the benefits of out-of-office (clinic) BP measurement to estimate extent of BP control and also prognosis. The goal for BP treatment has also evolved and, for the first time in decades, there has been a suggestion that a lower-than-140/90 mmHg target is associated with further reduction in adverse cardiovascular outcomes. There is, however, a need for more pills and an increased risk of treatment-related side effects. The choice of which anti-hypertensive to use, as well as the goal of treatment, should be individualised and discussed with the patient.
随着新的研究为我们提供更多的证据,高血压的管理将继续发展,这是一种非常常见的疾病。为了定义高血压,我们需要能够准确测量血压(BP),并使其易于重现。水银血压计一直是测量血压的标准工具,但很明显,它很快就会被逐步淘汰,取而代之的是电子血压设备——无论是诊所还是家庭使用。越来越多的人意识到门诊外血压测量对血压控制程度的评估和预后的好处。BP治疗的目标也发生了变化,几十年来第一次有证据表明,低于140/90 mmHg的目标与进一步减少心血管不良结局有关。然而,需要更多的药物和增加治疗相关副作用的风险。选择使用哪种抗高血压药物,以及治疗目标,应个体化并与患者讨论。
{"title":"Updates in Hypertension Management - 2017","authors":"T. Lau","doi":"10.33591/sfp.43.1.u3","DOIUrl":"https://doi.org/10.33591/sfp.43.1.u3","url":null,"abstract":"Management of hypertension will continue to evolve as new studies provide us more evidence on many relevant aspects of care for this very common condition. To define hypertension, we need to be able to measure blood pressure (BP) accurately and make it easily reproducible. The mercury sphygmomanometer has been a standard tool to measure BP, but it is evident that it will be phased out soon and replaced by electronic BP devices — both for clinic and home use. There is increasingly more awareness of the benefits of out-of-office (clinic) BP measurement to estimate extent of BP control and also prognosis. The goal for BP treatment has also evolved and, for the first time in decades, there has been a suggestion that a lower-than-140/90 mmHg target is associated with further reduction in adverse cardiovascular outcomes. There is, however, a need for more pills and an increased risk of treatment-related side effects. The choice of which anti-hypertensive to use, as well as the goal of treatment, should be individualised and discussed with the patient.","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124186024","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Complications of Diabetes Mellitus: Prevention in Type 2 Diabetes Mellitus 糖尿病并发症:2型糖尿病的预防
Pub Date : 2019-01-01 DOI: 10.33591/sfp.45.1.u3
Chew Ek Kwang, Quek Peng Lim
{"title":"Complications of Diabetes Mellitus: Prevention in Type 2 Diabetes Mellitus","authors":"Chew Ek Kwang, Quek Peng Lim","doi":"10.33591/sfp.45.1.u3","DOIUrl":"https://doi.org/10.33591/sfp.45.1.u3","url":null,"abstract":"","PeriodicalId":435054,"journal":{"name":"Singapore family physicians","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126996056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Singapore family physicians
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1